Orphanet Journal of Rare Diseases

Table 4 Course of liver enzyme levels in patients initially treated with zinc, grouped by treatment response

From: Zinc monotherapy is effective in Wilson’s disease patients with mild liver disease diagnosed in childhood: a retrospective study

			Median UI/L (range)	P value
ALT (UI/L)	Baseline	Responder	201 (12–502)	.30
	Baseline	Non-responder	57 (50–64)	.30
	6 months	Responder	72 (24–233)	.93
	6 months	Non-responder	82 (64–101)	.93
	12 months	Responder	51 (26–94)	≤.001
	12 months	Non-responder	172 (132–212)	≤.001
	24 months	Responder	41 (23-80)	-
	24 months	Non-responder	-	-
	>36 months	Responder	49 (18-79)
	>36 months	Non-responder	-
AST (UI/L)	Baseline	Responder	67 (22–168)	.42
	Baseline	Non-responder	59 (49–69)	.42
	6 months	Responder	46 (34–83)	.81
	6 months	Non-responder	56 (48–64)	.81
	12 months	Responder	44 (35–66)	≤.001
	12 months	Non-responder	156 (92–221)	≤.001
	24 months	Responder	40 (26-74)	-
	24 months	Non-responder	-	-
	>36 months	Responder	36 (19-61)	-
	>36 months	Non-responder	-	-
GGT (UI/L)	Baseline	Responder	36 (13–119)	.34
	Baseline	Non-responder	18 (16–21)	.34
	6 months	Responder	30 (13–49)	.35
	6 months	Non-responder	40 (22–59)	.35
	12 months	Responder	22 (11–55)	≤.001
	12 months	Non-responder	86 (45–127)	≤.001
	24 months	Responder	18 (13-38)	-
	24 months	Non-responder	-	-
	>36 months	Responder	16 (13-43)	-
	>36 months	Non-responder	-	-

Back to article page

ISSN: 1750-1172

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com